Search hospitals > Colorado > Denver
Rocky Mountain Cancer Centers-Rose
Claim this profileDenver, Colorado 80220
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Non-Small Cell Lung Cancer
159 reported clinical trials
2 medical researchers
Summary
Rocky Mountain Cancer Centers-Rose is a medical facility located in Denver, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Rocky Mountain Cancer Centers-Rose is involved with conducting 159 clinical trials across 344 conditions. There are 2 research doctors associated with this hospital, such as Nicholas DiBella and Keren Sturtz.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
97 reported clinical trials
182 drugs studied
Keren SturtzSCL Health Lutheran Medical Center9 years of reported clinical research
Studies Breast Cancer
Studies Carcinoma
4 reported clinical trials
14 drugs studied
Clinical Trials running at Rocky Mountain Cancer Centers-Rose
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Melanoma
Bladder Cancer
Cutaneous Melanoma
Tumors
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Questionnaire Choice
for Cancer Data Quality
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Recruiting1 award N/A11 criteria
Mobile Health
for Breast Cancer
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Recruiting1 award N/A10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Rocky Mountain Cancer Centers-Rose?
Rocky Mountain Cancer Centers-Rose is a medical facility located in Denver, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Non-Small Cell Lung Cancer and other specialties. Rocky Mountain Cancer Centers-Rose is involved with conducting 159 clinical trials across 344 conditions. There are 2 research doctors associated with this hospital, such as Nicholas DiBella and Keren Sturtz.